{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Class (Stereo):
CHEMICAL (ACHIRAL)
Imirestat is an aldose reductase inhibitor patented by global medical company Alcon Laboratories for the late complications of diabetes.
Status:
Investigational
Source:
NCT03926182: Phase 1 Interventional Completed Healthy Male Volunteers
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:pudexacianinium chloride [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04515602: Phase 3 Interventional Not yet recruiting Epithelial Ovarian Cancer
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04173104: Early Phase 1 Interventional Active, not recruiting Brain Tumor
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03694444: Phase 1/Phase 2 Interventional Completed Gingivitis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03770988: Phase 2 Interventional Unknown status Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Poziotinib is an inhibitor of EGFR tyrosine kinase family. The drug is being tested in phase II of clinical trials for different cancers: breast cancer, lung adenocarcinoma, head and neck squamous cell carcinoma, HER-2 positive advanced gastric cancer (in combination with Paclitaxel and Trastuzumab).
Status:
Investigational
Source:
NCT02048488: Phase 1/Phase 2 Interventional Completed Solid Tumors
(2012)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Belizatinib, also known as TSR-011, is an orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors.
Status:
Investigational
Source:
NCT03781947: Phase 1 Interventional Completed Healthy
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Teverelix is a polypeptide gonadotropin-releasing hormone (GnRH) antagonist which was being developed by Ardana Bioscience for the treatment of prostate cancer and benign prostatic hyperplasia. Compared with other GnRH antagonists, Teverelix is characterized by relatively good water solubility, little in vitro aggregation, and low histamine-releasing potency, with a dose that produces the halfmaximal response. In preclinical studies, Teverelix has been shown to exert antiovulatory activity. In phase I clinical trials Teverelix shows pronounced luteinizing hormone and testosterone suppressive effects after single subcutaneous doses in healthy men.
Status:
Investigational
Source:
NCT00302302: Phase 1 Interventional Completed Blood Glucose
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
L-Arabinose is a monosaccharide extracted from plant gums, corn fiber and beet pulps. It is a poorly-absorbed, readily-available sweet-tasting pentose. L-Arabinose is known to suppress obesity by regulating the fasting blood glucose level and the insulin resistance index. L-arabinose is a non-caloric sugar. L-arabinose may inhibit intestinal sucrase activity and thereby delay sucrose digestion.
